Skip to main content
EJNMMI Research
Fig.3 | EJNMMI Research

Fig.3

From: Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes

Fig.3

Uptake of serotonin and MIBG in cultured human megakaryocytes (MK1-3) after 10 days of differentiation and in SERT- and NET-transfected HEK293 cells. Samples were co-incubated with no inhibitor (black bars) or with the SSRI citalopram (1 μM; white bars). a Serotonin uptake in three megakaryocytic cell culture batches from three different healthy adult HSPC donors (MK1-3), fibroblasts (FB), and HEK293 cells transfected with an empty vector (HEK-EV), NET (HEK-NET), or SERT (HEK-SERT). b MIBG uptake in MK1-3, fibroblasts (FB), transfected HEK293 cells (HEK-EV, HEK-NET, HEK-SERT). c Close-up view of panel B showing MIBG uptake in MK1-3. The difference in MIBG uptake between samples with and without citalopram was significant in all three batches (MK1: p = 0.043, MK2: p = 0.014, MK3: p = 0.002). Data represent mean + SD. Please note the different scales of the Y-axis. Asterisks were used to indicate significance levels: p < 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (***). Serotonin/MIBG uptake is expressed as nanomole of substrate uptake per milligram protein per hour

Back to article page